-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of sunitinib malate capsules for production of category 4, and it is expected to be approved in the near future, sprinting into the third domestic market.
Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.
Terminal sunitinib sales in public medical institutions in China
Source: Mi Nei.
In recent years, the domestic market for sunitinib has continued to expand.
Application status of 4 types of imitation of sunitinib malate capsules
Source: One-click search on Mi Nei.
At present, a total of 5 pharmaceutical companies in the domestic market have submitted applications for the listing of sunitinib malate capsules.
Source: Mi Neiwang database, NMPA